Skip to main content

Suga banking on Pfizer vaccine ending harsh winter

Japan’s state of emergency was extended to seven additional prefectures this week, with the declaration now covering more than half of national GDP. And there are early signs that the recovery in consumer spending is reversing even while restrictions still have a light touch. But regardless of how much worse the current wave of coronavirus gets, we expect the economy to rebound swiftly in Q2 and Q3 so long as vaccines can be swiftly and successfully rolled out.  With approval of the Moderna and AstraZeneca vaccines in Japan lagging behind, such a roll out rests on PM Suga being able to procure and administer the Pfizer/BioNTech vaccine without major hiccups.

Become a client to read more

This is premium content that requires an active Capital Economics subscription to view.

Already have an account?

You may already have access to this premium content as part of a paid subscription.

Sign in to read the content in full or get details of how you can access it

Register for free

Sign up for a free account to gain:

  • Unlock additional content
  • Register for Capital Economics events
  • Receive email updates and economist-curated newsletters
  • Request a free trial of our services


Get access